Figure 5.
Splenic and bone marrow structure in huTNFR1ecd × JAK2+/VF mice after αTNFR1 treatment. (A) Representative photomicrographs of hematoxylin and eosin (H&E)-stained spleen sections from untreated huTNFR1ecd × JAK2+/VF mice (n = 3) and JAK2WT mice (n = 2) and huTNFR1ecd × JAK2+/VF mice treated with αTNFR1 antibody (n = 2) or IgG (n = 2); original magnification ×200. (B) Representative microphotographs of H&E-stained bone marrow sections from untreated huTNFR1ecd × JAK2+/VF mice (n = 3) and JAK2WT mice (n = 2) and huTNFR1ecd × JAK2+/VF mice treated with αTNFR1 antibody (n = 2) or IgG (n = 2); original magnification ×400.

Splenic and bone marrow structure in huTNFR1ecd × JAK2+/VF mice after αTNFR1 treatment. (A) Representative photomicrographs of hematoxylin and eosin (H&E)-stained spleen sections from untreated huTNFR1ecd × JAK2+/VF mice (n = 3) and JAK2WT mice (n = 2) and huTNFR1ecd × JAK2+/VF mice treated with αTNFR1 antibody (n = 2) or IgG (n = 2); original magnification ×200. (B) Representative microphotographs of H&E-stained bone marrow sections from untreated huTNFR1ecd × JAK2+/VF mice (n = 3) and JAK2WT mice (n = 2) and huTNFR1ecd × JAK2+/VF mice treated with αTNFR1 antibody (n = 2) or IgG (n = 2); original magnification ×400.

Close Modal

or Create an Account

Close Modal
Close Modal